Exzolt Euroopan unioni - suomi - EMA (European Medicines Agency)

exzolt

intervet international b.v. - fluralaner - ektoparasiticidit, hyönteismyrkyt ja karkotteet - kana - siipikarjan punasolun (dermanyssus gallinae) infektio hoidossa kanojen, kasvattajien ja keräyskanojen osalta.

Innovax-ND-IBD Euroopan unioni - suomi - EMA (European Medicines Agency)

innovax-nd-ibd

intervet international b.v. - solu-liittyvät live rekombinantti kalkkunan herpesvirus (kanta hvp360), ilmaista fusion proteiini nd virus ja vp2 proteiini ibd-viruksen - lintuinfluenssan herpes virus (marek ' s disease) + lintuinfluenssan gumboron tautiviruksen (gumboro-tauti) + newcastlen tauti-viruksen/paramyksoviruksen - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Rabitec Euroopan unioni - suomi - EMA (European Medicines Agency)

rabitec

ceva santé animale - heikennetty elävä raivotautirokotusvirus, kanta spbn gasgas - immunologisia valmisteita varten canidae, elävät virusrokotteet - red foxes (vulpes vulpes); raccoon dogs (nyctereutes procyonoides) - kettujen ja supikoirien aktiiviseen immunisointiin raivotautia vastaan ​​tartunnan ja kuolleisuuden estämiseksi.

Ubac Euroopan unioni - suomi - EMA (European Medicines Agency)

ubac

laboratorios hipra, s.a. - lipoteichoic acid peräisin biofilmin kiinnittyminen osa streptococcus uberis, kanta 5616 - bovidae-immunologiset ominaisuudet - karja - aktiivinen immunisointi terveiden lehmien ja hiehojen vähentämään kliinisiä utareensisäiseen aiheuttamien infektioiden streptococcus uberis, vähentää somaattisten solujen määrä in streptococcus uberis positiivinen neljänneksellä maitonäytteet ja vähentää maidontuotannon tappiot aiheuttama streptococcus uberis utareensisäiseen infektioita.

Isemid Euroopan unioni - suomi - EMA (European Medicines Agency)

isemid

ceva santé animale - torasemidin - korkea katto diureetit, sulfonamidit, tavallinen - koirat - hoitoon kliinisiä oireita liittyvät sydämen vajaatoiminta koirilla, mukaan lukien keuhkopöhö.

Tulissin Euroopan unioni - suomi - EMA (European Medicines Agency)

tulissin

virbac s.a. - tulatromysiini - systeemiseen käyttöön tarkoitetut antibakteerit - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. taudin läsnäolo karjassa olisi perustettava ennen metafylaktista hoitoa. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. taudin läsnäolo karjassa olisi perustettava ennen metafylaktista hoitoa. the product should only be used if pigs are expected to develop the disease within 2–3 days. lampaat: tarttuvan pododermatiitin (jalkajuhla) alkuvaiheen hoito, johon liittyy virulentti dichelobacter nodosus, joka vaatii systeemistä hoitoa.

Vectormune FP ILT + AE Euroopan unioni - suomi - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kana - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Innovax-ND-ILT Euroopan unioni - suomi - EMA (European Medicines Agency)

innovax-nd-ilt

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - immunologiset lääkkeet - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

NexGard Combo Euroopan unioni - suomi - EMA (European Medicines Agency)

nexgard combo

boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - kissat - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. eläinlääke on tarkoitettu yksinomaan, kun kaikki kolme ryhmää ovat suunnattu samaan aikaan.

CircoMax Myco Euroopan unioni - suomi - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiset suidaeille - siat (lihotus) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.